Status:
WITHDRAWN
Biomarker for Morquio Disease (BioMorquio)
Lead Sponsor:
CENTOGENE GmbH Rostock
Conditions:
Morquio Syndrome
Accumulation of Mucopolysaccharides
Eligibility:
All Genders
12+ years
Brief Summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Morquio disease from plasma
Detailed Description
Morquio syndrome (mucopolysaccharidosis type IV; MPS IV) is a mucopolysaccharide storage disease that exists in two forms (Morquio syndromes A and B) and occurs because of a deficiency of the enzymes ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Informed consent will be obtained from the patient or the parents before any study related procedures
- Patients older than 12 months
- The patient has a diagnosis of Morquio disease
- EXCLUSION CRITERIA:
- No Informed consent from the patient or the parents before any study related procedures.
- Patients younger than 12 months
- The patient has no diagnosis of Morquio disease
Exclusion
Key Trial Info
Start Date :
August 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01457456
Start Date
August 20 2018
End Date
February 28 2021
Last Update
February 13 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital, Faculty of Medicine, Ain Shams University
Cairo, Egypt, 89075
2
Centogene AG
Rostock, Germany, 18055
3
Amrita Institute of Medical Sciences & Research Centre
Kochi, Kerala, India, 682041
4
Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)
Mumbai, India, 400705